RU95105973A - Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза - Google Patents
Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмозаInfo
- Publication number
- RU95105973A RU95105973A RU95105973/14A RU95105973A RU95105973A RU 95105973 A RU95105973 A RU 95105973A RU 95105973/14 A RU95105973/14 A RU 95105973/14A RU 95105973 A RU95105973 A RU 95105973A RU 95105973 A RU95105973 A RU 95105973A
- Authority
- RU
- Russia
- Prior art keywords
- toxoplasmosis
- ring
- treatment
- rifamycin
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Abstract
Предложен способ снижения тяжести токсоплазмоза, обусловленного заражением пациента Toxoplasma gondii с помощью введения пациенту при необходимости такого лечения или после заражения, или перед воздействием инфекции терапевтически эффективного количества соединения, которое является спиропиперидиновым производным рифамицина S, где производное содержит имидазольное кольцо, которое включает атомы углерода в положениях 3 и 4 рифамицинового кольца, атом углерода в положении 2 имидазольного кольца, являющийся также атомом углерода пиперидинового кольца, образует таким образом спиропиперидиновую систему колец, необязательно содержащую низший углеводородный заместитель у атома азота пиперидина.
Claims (1)
- Предложен способ снижения тяжести токсоплазмоза, обусловленного заражением пациента Toxoplasma gondii с помощью введения пациенту при необходимости такого лечения или после заражения, или перед воздействием инфекции терапевтически эффективного количества соединения, которое является спиропиперидиновым производным рифамицина S, где производное содержит имидазольное кольцо, которое включает атомы углерода в положениях 3 и 4 рифамицинового кольца, атом углерода в положении 2 имидазольного кольца, являющийся также атомом углерода пиперидинового кольца, образует таким образом спиропиперидиновую систему колец, необязательно содержащую низший углеводородный заместитель у атома азота пиперидина.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5728893A | 1993-05-05 | 1993-05-05 | |
US08/057,288 | 1993-05-05 | ||
US08/203,539 | 1994-02-28 | ||
US08/203,539 US5529994A (en) | 1993-05-05 | 1994-02-28 | Treatment for toxoplasmosis |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95105973A true RU95105973A (ru) | 1997-01-20 |
RU2121838C1 RU2121838C1 (ru) | 1998-11-20 |
Family
ID=26736295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95105973A RU2121838C1 (ru) | 1993-05-05 | 1994-04-29 | Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза |
Country Status (14)
Country | Link |
---|---|
US (5) | US5670496A (ru) |
EP (1) | EP0648121B1 (ru) |
JP (1) | JPH07509003A (ru) |
AT (1) | ATE143601T1 (ru) |
AU (1) | AU669300B2 (ru) |
CA (1) | CA2138643A1 (ru) |
DE (1) | DE69400631T2 (ru) |
DK (1) | DK0648121T3 (ru) |
ES (1) | ES2095772T3 (ru) |
GR (1) | GR3021828T3 (ru) |
IL (1) | IL109543A (ru) |
NO (1) | NO950030D0 (ru) |
RU (1) | RU2121838C1 (ru) |
WO (1) | WO1994025038A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
GB9424013D0 (en) * | 1994-11-29 | 1995-01-18 | Wellcome Found | Medicaments |
US6579854B1 (en) | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US6258532B1 (en) | 1997-08-14 | 2001-07-10 | Vanderbilt University | Methods for in vitro susceptibility testing of chlamydia |
US6890526B2 (en) * | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
WO2000057187A2 (en) * | 1999-03-19 | 2000-09-28 | Vanderbilt University | Diagnosis and treatment of multiple sclerosis |
US7074832B2 (en) | 2001-09-24 | 2006-07-11 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US6429231B1 (en) * | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
US6858083B2 (en) * | 2002-06-05 | 2005-02-22 | Scimed Lifesystems, Inc. | Apparatus and method for closed-loop control of RF generator for welding polymeric catheter components |
US20030017985A1 (en) * | 2002-07-02 | 2003-01-23 | Taylor Gregory Alan | Molecules that influence pathogen resistance |
DE102004055316A1 (de) * | 2004-11-16 | 2006-05-18 | Bayer Healthcare Ag | Verhinderung vertikaler Endoparasiten-Infektionen |
TW201233389A (en) | 2005-10-05 | 2012-08-16 | Otsuka Pharma Co Ltd | Antituberculous therapeutic drugs and kit containing the same |
US7799885B2 (en) * | 2005-11-30 | 2010-09-21 | Corning Incorporated | Photo or electron beam curable compositions |
US20090054380A1 (en) * | 2005-12-20 | 2009-02-26 | Greenstein Robert J | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection |
SG10201405158QA (en) * | 2006-02-24 | 2014-10-30 | Callida Genomics Inc | High throughput genome sequencing on dna arrays |
FR2944014A1 (fr) | 2009-04-06 | 2010-10-08 | Univ Grenoble 1 | Peptides cycliques a activite antiparasitaire |
CN114601840A (zh) * | 2020-12-08 | 2022-06-10 | 复旦大学附属中山医院 | 一种联合用药,用于治疗卡氏肺孢子虫肺炎 |
CN113230248A (zh) * | 2021-06-18 | 2021-08-10 | 宁波大学 | 利卡灵-b及其组合物在制备治疗或预防弓形虫病药物中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644616A (en) * | 1969-03-24 | 1972-02-22 | Ciba Geigy Corp | Synergistic composition of rifampicin and streptomycin |
US4054663A (en) * | 1974-12-23 | 1977-10-18 | Sankyo Company Limited | Pyridine derivatives and their use as anticoccidial agents |
US4094982A (en) * | 1975-05-15 | 1978-06-13 | Sankyo Company Limited | Pyridine sulfonamides and their use as anticoccidial agents |
IT1056272B (it) * | 1975-06-13 | 1982-01-30 | Archifar Ind Chim Trentino | Prodotti derivati dalle amine aromatiche |
IT1135270B (it) * | 1980-04-12 | 1986-08-20 | Erba Farmitalia | 3-amidino-ansamicine |
US5175319A (en) * | 1983-04-14 | 1992-12-29 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
US5053432A (en) * | 1983-04-14 | 1991-10-01 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
DE3512194A1 (de) * | 1985-04-03 | 1986-10-09 | Hoechst Ag, 6230 Frankfurt | Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel |
WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
GB9000241D0 (en) * | 1990-01-05 | 1990-03-07 | Coopers Animal Health | Pharmaceutical use |
US5529994A (en) * | 1993-05-05 | 1996-06-25 | Palo Alto Medical Foundation | Treatment for toxoplasmosis |
-
1994
- 1994-04-29 DK DK94917283.7T patent/DK0648121T3/da active
- 1994-04-29 DE DE69400631T patent/DE69400631T2/de not_active Expired - Fee Related
- 1994-04-29 EP EP94917283A patent/EP0648121B1/en not_active Expired - Lifetime
- 1994-04-29 RU RU95105973A patent/RU2121838C1/ru active
- 1994-04-29 WO PCT/US1994/004765 patent/WO1994025038A1/en active IP Right Grant
- 1994-04-29 ES ES94917283T patent/ES2095772T3/es not_active Expired - Lifetime
- 1994-04-29 AT AT94917283T patent/ATE143601T1/de not_active IP Right Cessation
- 1994-04-29 CA CA002138643A patent/CA2138643A1/en not_active Abandoned
- 1994-04-29 AU AU69050/94A patent/AU669300B2/en not_active Ceased
- 1994-04-29 JP JP6524580A patent/JPH07509003A/ja active Pending
- 1994-05-04 IL IL109543A patent/IL109543A/en not_active IP Right Cessation
-
1995
- 1995-01-04 NO NO950030A patent/NO950030D0/no unknown
- 1995-06-07 US US08/476,508 patent/US5670496A/en not_active Expired - Fee Related
- 1995-06-07 US US08/487,721 patent/US5665707A/en not_active Expired - Fee Related
- 1995-06-07 US US08/481,689 patent/US5641769A/en not_active Expired - Fee Related
- 1995-06-07 US US08/474,998 patent/US5648345A/en not_active Expired - Fee Related
- 1995-06-07 US US08/481,741 patent/US5650405A/en not_active Expired - Fee Related
-
1996
- 1996-11-28 GR GR960403219T patent/GR3021828T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL109543A (en) | 1998-06-15 |
NO950030L (no) | 1995-01-04 |
IL109543A0 (en) | 1994-08-26 |
DK0648121T3 (ru) | 1997-02-24 |
EP0648121B1 (en) | 1996-10-02 |
AU669300B2 (en) | 1996-05-30 |
DE69400631D1 (de) | 1996-11-07 |
JPH07509003A (ja) | 1995-10-05 |
CA2138643A1 (en) | 1994-11-10 |
US5670496A (en) | 1997-09-23 |
RU2121838C1 (ru) | 1998-11-20 |
GR3021828T3 (en) | 1997-02-28 |
AU6905094A (en) | 1994-11-21 |
EP0648121A1 (en) | 1995-04-19 |
DE69400631T2 (de) | 1997-02-27 |
US5641769A (en) | 1997-06-24 |
US5650405A (en) | 1997-07-22 |
ATE143601T1 (de) | 1996-10-15 |
ES2095772T3 (es) | 1997-02-16 |
WO1994025038A1 (en) | 1994-11-10 |
US5648345A (en) | 1997-07-15 |
US5665707A (en) | 1997-09-09 |
NO950030D0 (no) | 1995-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95105973A (ru) | Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза | |
NO20022014L (no) | En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon | |
ATE108657T1 (de) | Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus. | |
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
DE69329400T2 (de) | L-Dopa Ester enthaltende Zusammensetzung | |
NO166448C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner. | |
KR910019618A (ko) | 발기부전증 치료용 제약 조성물 | |
LU88684I2 (fr) | Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet ) | |
KR970025615A (ko) | 암 전이 억제제 | |
ATE268174T1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
GB9108629D0 (en) | Heterocyclic pharmaceutical compounds,preparation and use | |
RU94045866A (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения | |
OA07029A (fr) | Le chlorure de gallium, nouveau médicament anti-cancéreux. | |
KR880004810A (ko) | 소화성 궤양 치료제 | |
KR960700711A (ko) | 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases) | |
KR930702985A (ko) | 식도암의 치료 | |
KR900701273A (ko) | 진토성 에르골린 유도체 | |
KR930702984A (ko) | 비-소세포 폐암의 치료 | |
KR830009776A (ko) | 세포 보호 유도방법 | |
SE8804640D0 (sv) | Medicament comprising cyclolinopeptide a | |
KR930702983A (ko) | 난소암의 치료 | |
CA2080040A1 (en) | Methods for preventing mycobacterial infections by administration of rifabutin | |
KR940002268A (ko) | 21-클로로-프레그난 유도체 | |
KR950700063A (ko) | 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress) |